Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239139 | 0.83 | MAPKAPK2 (0.31) | ATR | |
| SCHEMBL10618564 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1KMT2AATRHTT | |
| SCHEMBL10852237 | 0.77 | NOS1 (0.35) | KDM4EHSD17B10ALDH1A1KMT2AHTT | |
| SCHEMBL12020095 | 0.76 | MAPKAPK2 (0.36) | KDM4EHSD17B10ALDH1A1KMT2AHTT | |
| SCHEMBL10852133 | 0.76 | ALOX5AP (0.34) | KDM4EALDH1A1KMT2AHTTHPGD | |
| SCHEMBL7532545 | 0.76 | CUL4A (0.37) | KDM4EHSD17B10ALDH1A1KMT2AHTT | |
| SCHEMBL10847658 | 0.75 | NOS1 (0.45) | KDM4EHSD17B10ALDH1A1KMT2AHTT | |
| SCHEMBL2959006 | 0.75 | ALDH1A1 (0.38) | KDM4EHSD17B10ALDH1A1KMT2AHPGD | |
| SCHEMBL23028915 | 0.73 | MAPK1 (0.40) | KDM4EHSD17B10ALDH1A1KMT2APOLB | |
| SCHEMBL4697307 | 0.73 | SYK (0.32) | ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1966187-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007071952-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| EP-0048002-A2 | Method for preparing N-(4-(((2,4-diamino-6-pteridinyl)-methyl)methylamino)benzoyl)glutamic acid | Farmos Group Ltd. (FI) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | AMPD1, AMPD2, AMPD3 | KDM4E 864/4885HSD17B10 729/4885ALDH1A1 1250/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | KDM4E 4628/4885HSD17B10 3670/4885ALDH1A1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.